Promising combo for tough CLL cases hits early snag
NCT ID NCT04230304
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a combination of two drugs—daratumumab and ibrutinib—in people with chronic lymphocytic leukemia (CLL) that had come back or stopped responding to treatment. The goal was to see if the combo could shrink or eliminate cancer better than ibrutinib alone. Only 8 people took part before the study was stopped early, so the results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daratumumab and ibrutinib
- What this could lead to
- If this combination works, it could offer a more effective treatment option for patients with CLL that has returned or not responded to prior therapy.
- What could go wrong
- This was a very small, early-phase trial that was terminated early, so results are limited. The combination may not prove better than ibrutinib alone and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Engineered immune cells take on tough blood cancers in early trial
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Blood cancer transplant study tests safer GVHD prevention
- Stem cell transplant study seeks best way to prevent immune attack
- New trial aims to bring targeted lymphoma drugs to minority patients